REPL Replimune: Projected Price to Earnings

The Replimune Group, Inc. (REPL) price chart on GURU.Markets demonstrates the 0.00 indicator, while the business relies on external contractors for vaccine testing, which mitigates resource risks. The development of anti-tumor drugs is conducted under the leadership of top virology experts. Experienced management effectively coordinates medical research, maintaining the loyalty of strategic partners and shareholders.

replimune.com - REPL Future Price to Earnings Multiple (period 07/04/2022 - 11/11/2026)

Metric breakdowns and analytics for Replimune Inc. (REPL)

- stock quotes and analyst forecast:

Stock Price Replimune|REPL - Analyst Target Range

- company stock capitalization data:

Market Valuation Replimune Group Inc|REPL - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Replimune|REPL - Accounting Value of Company|Market Capitalization to Book Value Ratio replimune.com|REPL - Company Total Asset Base

- debt level and financial liquidity data:

- financial results and valuation multiples details:

REPL - Company Net Income|Future Profit Replimune Group, Inc.|REPL - Market Cap to Net Income Ratio|Projected Price to Earnings Replimune Corp|REPL - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Replimune Group Inc|REPL - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Replimune|REPL - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months replimune.com|REPL - Earnings per share increase in current year|Earnings growth forecast for next year Replimune Group, Inc.

Fundamental company analysis:Replimune REPL

Signature product of Replimune Group, Inc.

Forward P/E determines an asset's investment attractiveness through expected returns. This metric relates the current quote to projected net income, reflecting market expectations for business efficiency. By analyzing the forward price-to-earnings ratio of a company, an investor assesses the extent of the premium paid for future growth. For Replimune Group, Inc. (REPL), the stability of this indicator is supported by the implementation of energy-saving technologies and emissions filtration. These ESG initiatives reduce operational risks within the biotechnology sector.

Analysis of competing companies